Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia

Journal of Clinical Oncology

Volumn 28, Issue 8, 2010, Pages 1429-1435

  Burchert, Andreas ^a   Müller, Martin C ^a   Kostrewa, Philippe ^a   Erben, Philipp ^a   Bostel, Tilman ^a   Liebler, Simone ^a   Hehlmann, Rüdiger ^a   Neubauer, Andreas ^a   Hochhaus, Andreas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MESSENGER RNA; MYELOBLASTIN; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2A INTERFERON; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOIDOSIS; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECT; LYMPHOCYTE SUBPOPULATION; MIDDLE AGED; RECURRENT DISEASE; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON ALFA-2A; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MYELOBLASTIN; PIPERAZINES; PYRIMIDINES; RECURRENCE; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77950496740     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.5075     Document Type: Article

References (39)

1. Buchdunger E, Zimmermann J, Mett H, et al: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104, 1996
2. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, 1996
3. Druker BJ, Guilhot F, O'Brien SG, et al: Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006 (Pubitemid 44903745)
4. Graham SM, Jorgensen HG, Allan E, et al: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319-325, 2002
5. Jørgensen HG, Allan EK, Jordanides NE, et al: Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109:4016-4019, 2007 (Pubitemid 46641755)
6. Copland M, Hamilton A, Elrick LJ, et al: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 107:4532-4539, 2006 (Pubitemid 43801382)
7. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003 (Pubitemid 37211057)
8. Cortes J, O'Brien S, Kantarjian H: Discontinuation of imatinib therapy after achieving a molecular response. Blood 104:2204-2205, 2004 (Pubitemid 39297882)
9. Baccarani M, Saglio G, Goldman J, et al: Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820, 2006
10. Deininger MW, Holyoake TL: Can we afford to let sleeping dogs lie? Blood 105:1840-1841, 2005
11. Giles FJ, O'Dwyer M, Swords R: Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 23:1698-1707, 2009
12. Kiguchi T, Tauchi T, Ito Y, et al: Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leuk Res 33:506-508, 2009
13. Kasteng F, Sobocki P, Svedman C, et al: Economic evaluations of leukemia: A review of the literature. Int J Technol Assess Health Care 23:43-53, 2007 (Pubitemid 46648299)
14. Kolb HJ, Schattenberg A, Goldman JM, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050, 1995
15. Hochhaus A, Reiter A, Saußele S, et al: Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission. Blood 95:62-66, 2000 (Pubitemid 30017225)
16. Bonifazi F, de Vivo A, Rosti G, et al: Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders. Blood 98:3074-3081, 2001
17. Kantarjian HM, O'Brien S, Cortes JE, et al: Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent longterm prognosis. Cancer 97:1033-1041, 2003 (Pubitemid 36173155)
18. Burchert A, Neubauer A: Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk Lymphoma 46:167-175, 2005 (Pubitemid 40185945)
19. Molldrem J, Dermime S, Parker K, et al: Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88:2450-2457, 1996 (Pubitemid 26327493)
20. Molldrem JJ, Lee PP, Wang C, et al: Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6:1018-1023, 2000
21. Burchert A, Wolfl S, Schmidt M, et al: Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101:259-264, 2003 (Pubitemid 36025916)
22. Gannagé M, Abel M, Michallet AS, et al: Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: Implications for vaccine development and adoptive cellular immunotherapy. J Immunol 174:8210-8218, 2005 (Pubitemid 40806333)
23. Mahon FX, Delbrel X, Cony-Makhoul P, et al: Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20:214-220, 2002 (Pubitemid 34032614)
24. Hughes T, Deininger M, Hochhaus A, et al: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28-37, 2006 (Pubitemid 43990609)
25. Emig M, Saussele S, Wittor H, et al: Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13:1825-1832, 1999
26. Mohty M, Yong AS, Szydlo RM, et al: The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110:380-383, 2007 (Pubitemid 47026858)
27. Bhatia R, Holtz M, Niu N, et al: Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101:4701-4707, 2003 (Pubitemid 36857723)
28. Rousselot P, Huguet F, Rea D, et al: Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58-60, 2007 (Pubitemid 46053043)
29. Ghanima W, Kahrs J, Dahl TG 3rd, et al: Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur J Haematol 72:441-443, 2004 (Pubitemid 38703537)
30. Merante S, Orlandi E, Bernasconi P, et al: Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90:979-981, 2005 (Pubitemid 41020302)
31. Mahon FX, Rea D, Guilhot F, et al: Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients. Blood 114:353, 2009 (suppl; abstr 859)
32. Molldrem JJ, Lee PP, Kant S, et al: Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 111:639-647, 2003 (Pubitemid 36278582)
33. Dietz AB, Souan L, Knutson GJ, et al: Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104:1094-1099, 2004 (Pubitemid 39038030)
34. Seggewiss R, Lore K, Greiner E, et al: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105:2473-2479, 2005 (Pubitemid 40387048)
35. Gao H, Lee BN, Talpaz M, et al: Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19:1905-1911, 2005
36. Cwynarski K, Laylor R, Macchiarulo E, et al: Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18:1332-1339, 2004 (Pubitemid 39136740)
37. Brauer KM, Werth D, von Schwarzenberg K, et al: BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res 67:5489-5497, 2007 (Pubitemid 46997290)
38. Scheich F, Duyster J, Peschel C, et al: The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens. Blood 110:2556-2560, 2007 (Pubitemid 47523178)
39. Essers MA, Offner S, Blanco-Bose WE, et al: IFN alpha activates dormant haematopoietic stem cells in vivo. Nature 458:904-908, 2009